Novartis unveils fresh insights into Zolgensma's safety and performance, highlighting sustained and enhanced motor skills in SMA-affected children who are larger and older.

Cullinan Oncology Reveals FDA Approval for Initial Trials of Unique MICA/B Antibody, CLN-619, Targeting Advanced Multiple Myeloma Cases.

ATA3219, an off-the-shelf CAR T treatment by Atara Biotherapeutics, gets green light from the FDA for its IND submission targeting Lupus Nephritis.

UK regulators have approved Ariceum Therapeutics to initiate an early-stage trial with its innovative I-123 tagged PARP blocker for individuals experiencing repeated glioblastoma.

Jacobio Pharmaceuticals Secures U.S. Go-Ahead for Experimental P53 Y220C Stimulant JAB-30300 under Investigational New Drug Status.

Innovent Reveals Initial Subject Receives Dose in Australian Phase 1 Trial for IBI3002 (a dual-action antibody targeting IL-4Rα and TSLP).

Biocon Biologics, a fully owned arm of Biocon Ltd and a global player in biosimilars, announced today a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson.

FDA Grants ARTHEx Biotech Authorization to Start Early-Stage Clinical Study for ATX-01 in Treating Myotonic Dystrophy (DM1) under the ArthemiR™ Project.

Ironwood Pharma reveals encouraging initial findings from an international Phase III study of Apraglutide, a weekly treatment for Short Bowel Syndrome leading to Intestinal Failure in adults.

ImmPACT Bio Receives $8M from CIRM for Early-Stage Trial of Novel Dual-Target CAR T-Cell Treatment IMPT-514, Aimed at Tough-to-Treat Lupus Kidney Disease and Widespread Lupus Conditions.

Janux Therapeutics Reports Promising Preliminary Results on Tolerability and Therapeutic Impact in Progressive Dose Studies for Prostate Cancer Therapy JANX007 and Solid Cancer Treatment JANX008.

Alvotech and Teva have received FDA clearance for their product SIMLANDI® (adalimumab-ryvk), a novel substitutable biosimilar to Humira®.